Dewpoint Therapeutics
Dewpoint Therapeutics is a biotech company that integrates AI with advanced experimental technologies to develop transformative therapies targeting biomolecular condensates, with partnerships and recognition from leading global pharmaceutical companies and investors.
Company History
Dewpoint Therapeutics has garnered significant attention for its innovative approach to drug discovery. It has raised $287 million in series A, B, and C funding from 15 early investors. Dewpoint has been recognized by organizations such as Fierce Biotech, Endpoints, and Forbes for its contributions to biotech innovation.
Technological Platform
Dewpoint Therapeutics employs an integrated suite of technologies designed for the discovery of transformative condensate modulating therapies. The company's platform combines expertise from complementary state-of-the-art experimental technologies with a powerful AI platform. This integration accelerates the cycle time from disease to drug discovery.
Partnerships
Dewpoint Therapeutics maintains partnerships with several leading global pharmaceutical companies, including Bayer, Novo Nordisk, Evotec, and Chemify. The company also has potential revenues of $1.1 billion from these partnerships, excluding royalties.
Research Focus
Dewpoint Therapeutics focuses on condensate biology, which is believed to elucidate the underlying causes of complex diseases. The company's research areas include targeting biomolecular condensates to treat insulin resistance and diabetes progression, particularly in collaboration with Novo Nordisk.
Pipeline and Achievements
Dewpoint Therapeutics has developed a broad pipeline of discovery programs that target diseases once considered undruggable. The company plans to have 2 Investigational New Drug (IND) applications by 2025. Their efforts in ALS treatment have been recognized with the Target ALS Grant, and they have filed multiple patent applications for novel compositions of matter. Additionally, Dewpoint has foundational platform technology patents granted by the US Patent Office.